RESEARCH LITERACY / SOURCE NOTES
Peptide dosing: what is actually established?
There is no universal peptide dosing schedule. Approved-product instructions, doses used in a study and community schedules are different kinds of information. A study dose is not a personal recommendation.
Editorial draft · primary sources linked; not independently clinically reviewed.
Editorial update:
| Source of a number | What to retain | Boundary |
|---|---|---|
| Approved product label | Product, indication, jurisdiction and version | Individual prescribing remains clinical |
| Clinical study | Route, participants, duration and monitoring | Research is not a general protocol |
| Community schedule | Unverified origin and context | Not proof of safety or effectiveness |
First identify the product and indication
For a prescribed medicine, the relevant reference is the current local product information and the prescriber or pharmacist. Do not transfer instructions between different formulations, delivery devices or indications simply because the ingredient name matches.
The US EGRIFTA WR and EGRIFTA SV labels explicitly distinguish their formulations. Their product-specific instructions are not a template for an unlabelled research vial.
- DailyMed — EGRIFTA WR US prescribing information ↗Specific US product and indication; not a global approval statement.
- DailyMed — EGRIFTA SV US prescribing information ↗Separate US formulation; not interchangeable with WR.
Reading a research dose
Record the molecule, formulation, route, population, trial duration, comparison group and monitoring alongside any amount. A number without these fields is an incomplete research summary.
Retatrutide phase 2 results concern trial treatment under a defined design. They do not create an approved self-administration schedule. Short follow-up also cannot answer every longer-term safety question.
- Jastreboff et al., 2023 — retatrutide phase 2 obesity trial ↗Randomised phase 2 trial; abstract reviewed, not a prescribing label.
When no reliable human schedule is established
For an investigational material, the responsible answer may be “an established human dose has not been demonstrated in the sources reviewed.” A supplier’s starter guide, repeated anecdote or AI-generated schedule does not close that gap.
A mass in milligrams, a concentration and a device marking describe different quantities. Confusing them can change the interpreted amount. This guide does not provide reconstitution instructions, syringe conversions or escalation plans.
Bring a better question to a professional
For a prescribed product, ask whether the label matches the exact formulation and indication and what monitoring is required. If the material is not an approved medicine, ask about the lack of established quality, efficacy and safety rather than assuming a plausible schedule resolves it.
Our profile sections describe the type of dose evidence available. Private tracking records observations; it does not validate a regimen or recommend the next dose.
- FDA — concerns with unapproved GLP-1 drugs ↗US regulatory and product-quality context; subject to change.